Medicare Part B (Medical Insurance) covers FDA-authorized COVID-19 monoclonal antibody treatments, if all of these apply:
- You tested positive for COVID-19.
- You have a mild to moderate case of COVID-19.
- You’re at high risk of progressing to a severe case of COVID-19 and/or at high risk of requiring hospitalization.
You pay nothing for a monoclonal antibody treatment during the COVID-19 public health emergency (and for the rest of the calendar year in which the COVID-19 public health emergency ends) when you get it from a Medicare provider or supplier.
If you test positive for COVID-19 and have mild to moderate symptoms, these treatments can help fight the disease and keep you out of the hospital. This treatment involves an infusion of monoclonal antibodies (specifically bamlanivimab, or casirivimab and imdevimab) to treat COVID-19. Health care providers can only give the infusions in certain settings.
Medicare also covers COVID-19 diagnostic tests, COVID-19 antibody tests, and COVID-19 vaccines.